Seeking Alpha

Peregrine Pharmaceuticals (PPHM +9.1%) moves up after its FQ1 beat estimates across the board on...

Peregrine Pharmaceuticals (PPHM +9.1%) moves up after its FQ1 beat estimates across the board on fewer than anticipated losses, despite a double digit Y/Y decline in total revenue. The stock soared on Friday, after the company said a recent Phase IIb trial of its lung cancer treatment bavituximab produced interim data showing statistically significant improvement in overall survival.

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs